Personalization of Treatment is the Way Forward in Care and Trials.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
received:
02
03
2020
revised:
18
03
2020
accepted:
03
04
2020
pubmed:
9
4
2020
medline:
7
1
2021
entrez:
9
4
2020
Statut:
ppublish
Résumé
It has been demonstrated that, in early breast cancer, there is no survival benefit to additional treatment once a patient has achieved a pathologic complete response (pCR). Together with the well-established prognostic association between pCR and survival, this presents a strong rationale for escalation/deescalation of neoadjuvant treatment based upon response.
Identifiants
pubmed: 32265219
pii: 1078-0432.CCR-20-0604
doi: 10.1158/1078-0432.CCR-20-0604
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
2771-2773Subventions
Organisme : NCI NIH HHS
ID : P01 CA210961
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentOn
Informations de copyright
©2020 American Association for Cancer Research.